FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3183679003> ?p ?o ?g. }

• W3183679003 startingPage "5420" @default.
• W3183679003 abstract "Abstract Background: Multiple Myeloma (MM) accounts for 1.6% of all cancers and 5-10% of hematologic malignancies in the United States. Novel therapeutic agents have raised the overall survival from 1-2 years to 7-8 years with meaningful improvement in quality of life. Ongoing clinical trials have significantly contributed to the favorable disease outcomes, however many of these interventions still remain unknown to clinicians. The significance of citation analysis lies in the fact that clinicians often modify their management strategy based on research published in high impact journals. In this article, our main objective is to assist medical professionals working in the field to identify the most influential research published on MM. Materials and methods: We conducted a bibliographic analysis on the Web of Science (WOS). Included journals were those listed in the Science Citation Index Expanded, without specific restrictions on the journals. We retrieved the articles for analysis by typing “Multiple Myeloma” into WOS search box and conducted this data search in Title setting with application of English language filter on 07-25-2017. Results: We identified 27,718 articles published between 1901 and 2017, ranked the articles on the basis of citation frequency from highest to lowest and thereafter shortlisted the top 100 cited articles. The most cited article received 2404 citations. Top 100 cited articles were published between 1990 and 2007. In our analysis, we found that highest number of articles were published in the year 2007 (Table 1). 44 out of 100 articles were published in journals with impact factor (IF) greater than 20. The journal with highest number of publications (36%) was BLOOD (IF 13.16). The country with leading number of publication on MM was the United States of America (77%), followed by France (20%), Italy (15%), and the United Kingdom (15%) (Table 2). The production of these 100 articles originated from 50 centers, the most significant contributors out of which were VA Boston Healthcare system and Harvard University each with 36% of total articles, followed by Dana-Farber with 34% of the total articles. Anderson KC., was found to be most frequently cited common author with his contributions amounting up to 26% of the total (Table 3). Maximum studies were found to be categorized under the title of hematology (40%), followed by general internal medicine (29%) and oncology (27%). Discussion: MM research has gone through milestones in areas including disease staging, pathogenesis and management. Seven articles focused on staging, 29 on disease pathogenesis and 51 on treatment. Two of the top ten most cited articles were aimed at staging. Clinical staging was proposed by Durie BGM et al., although the most cited article in our list is no longer the primary staging system. Current classification of MM is based on revised international staging system and disease cytogenetics. Second most frequently encompassed category was disease pathogenesis. Over the years, understanding of pathogenesis has laid the foundation for development of novel therapeutic agents. Among the top 100 cited articles, only 7 studies were focused on bortezomib containing regimens, whereas none of them included carfilzomib or Ixazomib based novel therapeutic regimens. This shows that articles with high frequency of citations mostly consist of early-published articles. Among the top 100 list, only two articles were from 2012 (latest year on the list). To capture important and latest research, a second search was carried out with strategy to limit articles published during last five years. Conclusion: A bibliographic analysis of top cited articles published focused on disease staging, pathogenesis and management. Search limited to last five years (2012-2017) portrayed different results from our original search. None of the studies in the last 5 years list were included in the original list due to less number of total citations received. Recent studies focused on latest developments including therapeutic agents such as novel proteasome inhibitors (carfilzomib, Ixazomib) and monoclonal antibodies (daratumumab, eculizumab) among others. Hence we can infer that top cited article set the stage with deeper understating about MM and helped make solid foundations for the latest developments in the field. We continue to expect ground breaking discoveries be shared through medical scientific literature. Download : Download high-res image (144KB) Download : Download full-size image Disclosures No relevant conflicts of interest to declare." @default.
• W3183679003 created "2021-08-02" @default.
• W3183679003 creator A5005991606 @default.
• W3183679003 creator A5010399827 @default.
• W3183679003 creator A5024711213 @default.
• W3183679003 creator A5053509474 @default.
• W3183679003 creator A5056633996 @default.
• W3183679003 creator A5059430672 @default.
• W3183679003 creator A5061557104 @default.
• W3183679003 creator A5089580443 @default.
• W3183679003 date "2017-12-08" @default.
• W3183679003 modified "2023-09-28" @default.
• W3183679003 title "Disease Milestones through Bibliometeric Analysis of Top 100 Cited Articles in Multiple Myeloma" @default.
• W3183679003 doi "https://doi.org/10.1182/blood.v130.suppl_1.5420.5420" @default.
• W3183679003 hasPublicationYear "2017" @default.
• W3183679003 type Work @default.
• W3183679003 sameAs 3183679003 @default.
• W3183679003 citedByCount "0" @default.
• W3183679003 crossrefType "journal-article" @default.
• W3183679003 hasAuthorship W3183679003A5005991606 @default.
• W3183679003 hasAuthorship W3183679003A5010399827 @default.
• W3183679003 hasAuthorship W3183679003A5024711213 @default.
• W3183679003 hasAuthorship W3183679003A5053509474 @default.
• W3183679003 hasAuthorship W3183679003A5056633996 @default.
• W3183679003 hasAuthorship W3183679003A5059430672 @default.
• W3183679003 hasAuthorship W3183679003A5061557104 @default.
• W3183679003 hasAuthorship W3183679003A5089580443 @default.
• W3183679003 hasConcept C126322002 @default.
• W3183679003 hasConcept C159110408 @default.
• W3183679003 hasConcept C161191863 @default.
• W3183679003 hasConcept C17744445 @default.
• W3183679003 hasConcept C178315738 @default.
• W3183679003 hasConcept C199539241 @default.
• W3183679003 hasConcept C27415008 @default.
• W3183679003 hasConcept C2776312699 @default.
• W3183679003 hasConcept C2776364478 @default.
• W3183679003 hasConcept C2778805511 @default.
• W3183679003 hasConcept C2779455604 @default.
• W3183679003 hasConcept C2779473830 @default.
• W3183679003 hasConcept C41008148 @default.
• W3183679003 hasConcept C512399662 @default.
• W3183679003 hasConcept C71924100 @default.
• W3183679003 hasConceptScore W3183679003C126322002 @default.
• W3183679003 hasConceptScore W3183679003C159110408 @default.
• W3183679003 hasConceptScore W3183679003C161191863 @default.
• W3183679003 hasConceptScore W3183679003C17744445 @default.
• W3183679003 hasConceptScore W3183679003C178315738 @default.
• W3183679003 hasConceptScore W3183679003C199539241 @default.
• W3183679003 hasConceptScore W3183679003C27415008 @default.
• W3183679003 hasConceptScore W3183679003C2776312699 @default.
• W3183679003 hasConceptScore W3183679003C2776364478 @default.
• W3183679003 hasConceptScore W3183679003C2778805511 @default.
• W3183679003 hasConceptScore W3183679003C2779455604 @default.
• W3183679003 hasConceptScore W3183679003C2779473830 @default.
• W3183679003 hasConceptScore W3183679003C41008148 @default.
• W3183679003 hasConceptScore W3183679003C512399662 @default.
• W3183679003 hasConceptScore W3183679003C71924100 @default.
• W3183679003 hasLocation W31836790031 @default.
• W3183679003 hasOpenAccess W3183679003 @default.
• W3183679003 hasPrimaryLocation W31836790031 @default.
• W3183679003 hasRelatedWork W1998134998 @default.
• W3183679003 hasRelatedWork W2003134879 @default.
• W3183679003 hasRelatedWork W2087427836 @default.
• W3183679003 hasRelatedWork W2239258930 @default.
• W3183679003 hasRelatedWork W2415416603 @default.
• W3183679003 hasRelatedWork W2559634387 @default.
• W3183679003 hasRelatedWork W2725799591 @default.
• W3183679003 hasRelatedWork W2740103518 @default.
• W3183679003 hasRelatedWork W2744718101 @default.
• W3183679003 hasRelatedWork W2765492995 @default.
• W3183679003 hasRelatedWork W2789433635 @default.
• W3183679003 hasRelatedWork W2795535525 @default.
• W3183679003 hasRelatedWork W2887544501 @default.
• W3183679003 hasRelatedWork W2921286516 @default.
• W3183679003 hasRelatedWork W3011876584 @default.
• W3183679003 hasRelatedWork W3027070815 @default.
• W3183679003 hasRelatedWork W3049372920 @default.
• W3183679003 hasRelatedWork W3094076634 @default.
• W3183679003 hasRelatedWork W3126679215 @default.
• W3183679003 hasRelatedWork W3212439502 @default.
• W3183679003 hasVolume "130" @default.
• W3183679003 isParatext "false" @default.
• W3183679003 isRetracted "false" @default.
• W3183679003 magId "3183679003" @default.
• W3183679003 workType "article" @default.